This week for our series “Getting By, Getting Ahead,” which looks at the personal stories behind New Hampshire’s economy, we’ve been focusing on start-ups in the Upper Valley. Bioengineering entrepreneur Tillman Gerngross was the subject of our latest profile. Recently, we discussed the regional start-up scene on All Things Considered.
!["We're in an industry that is not entirely recession-proof," says Adimab co-founder and CEO Tillman Gerngross. "But the drug industry is a lot less volatile and subject to discretionary spending, because people get sick and they need drugs. Fortunately, we've been able to establish a sort of leadership position in the discovery of antibody-based therapies, and [the pharmaceutical industry] is very interested in accessing that capability."](http://stateimpact.npr.org/new-hampshire/files/2012/06/IMG_1088-100x100.jpg "Tillman Gerngross Portrait")
As part of our weekly “Getting By, Getting Ahead” series, StateImpact is traveling across New Hampshire, gathering personal stories from the people behind the economy. In our third installment, we visit a biotech start-up in the Dartmouth-Lake Sunapee region. _____ Deep inside a nondescript business park in Lebanon, a blocky, industrial building is getting a [...]
Tomorrow morning on NHPR, we’ll hear from Tillman Gerngross, a bioengineering entrepreneur in the Upper Valley. Tillman’s story is Part Three of our series “Getting By, Getting Ahead,” examining how people across New Hampshire’s seven regions are navigating a recovering economy. [...]
StateImpact seeks to inform and engage local communities with broadcast and online news focused on how state government decisions affect your lives.
Learn More »